Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | MLNR | O43193 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242102 | 0.94 | LMNA (0.31) | PTPN1LMNATDP1 | |
| SCHEMBL137086 | 0.94 | LMNA (0.31) | PTPN1LMNATDP1 | |
| SCHEMBL3242091 | 0.93 | LMNA (0.30) | LMNATDP1 | |
| SCHEMBL2065361 | 0.92 | ALDH1A1 (0.31) | PTPN1TBXA2R | |
| SCHEMBL8116380 | 0.92 | PTPN1 (0.33) | PTPN1 | |
| SCHEMBL2064627 | 0.91 | LMNA (0.38) | LMNATDP1 | |
| SCHEMBL45521 | 0.90 | LMNA (0.33) | LMNATDP1 | |
| SCHEMBL2919493 | 0.88 | ALDH1A1 (0.32) | — | |
| SCHEMBL3239950 | 0.88 | ALDH1A1 (0.32) | — | |
| SCHEMBL3239936 | 0.87 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773750-B1 | FORMULATION AND METHOD OF PREPARATION | GE HEALTHCARE AS (NO) | 2022-04-20 | — | — | EP | disclosed |
| US-20210046195-A1 | FORMULATION AND METHOD OF PREPARATION | GE HEALTHCARE AS (NO) | 2021-02-18 | — | — | US | disclosed |
| US-8529874-B2 | Peptide imaging agents | GE HEALTHCARE AS (NO) | 2013-09-10 | — | — | US | disclosed |
| EP-2146749-B1 | LABELLED HGF BINDING PEPTIDES FOR IMAGING | GE HEALTHCARE AS (NO) | 2012-03-28 | — | — | EP | disclosed |
| US-20110268660-A1 | METHOD FOR DETECTING DYSPLASIA | GE HEALTHCARE AS (NO) | 2011-11-03 | — | — | US | disclosed |
| US-20100303727-A1 | OPTICAL IMAGING AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100150843-A1 | PEPTIDE IMAGING AGENTS | GE HEALTHCARE AS (NO) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046195-A1 | FORMULATION AND METHOD OF PREPARATION | IAPP, LPXN, KIT | PTPN1 1030/4885MLNR 50/4885NR1I2 4593/4885 |
| US-20100303727-A1 | OPTICAL IMAGING AGENTS | MSN, SIGLEC7, FABP7 | PTPN1 741/4885MLNR 216/4885NR1I2 1954/4885 |
| US-20100150843-A1 | PEPTIDE IMAGING AGENTS | VIP, RXFP1, GRPR | PTPN1 4414/4885MLNR 10/4885NR1I2 905/4885 |
| US-20110268660-A1 | METHOD FOR DETECTING DYSPLASIA | EGFR, ERBB2, ERBB3 | PTPN1 2975/4885MLNR 58/4885NR1I2 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.